{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:25:45Z","timestamp":1793226345601,"version":"4.5.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i) have improved the efficacy of endocrine therapy in hormone receptor-positive (HR+)\/human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) and are now used in both early-stage and metastatic disease. Recent case reports suggest that pseudo-serum creatinine (Scr) elevations are likely a class effect of CDK4\/6i.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective analysis included patients aged \u226518 years who received at least one dose of palbociclib, ribociclib, or abemaciclib for the treatment of HR+\/HER2- BC in the early or advanced setting. The primary objective was the incidence of pseudo-Scr elevation for each of the three agents. CDK4\/6i-induced pseudo-Scr elevation was suspected when the Scr elevation could not be fully attributed to other causes. Secondary endpoints included the grade, onset, duration, and clinical consequences of pseudo-Scr elevation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      143 patients were included. Pseudo-Scr elevation was suspected in patients treated with palbociclib, ribociclib, or abemaciclib, with incidences of 16% (8\/50), 14% (6\/43), and 20% (10\/50), respectively. Rates did not significantly differ between agents (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.727). Among patients with CDK4\/6i-induced pseudo-Scr elevation, all events were grade 1 (8.3%) or 2 (91.7%). The median onset from treatment initiation to first Scr elevation was 33.5, 42, and 21.5 days, for palbociclib, ribociclib, or abemaciclib, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pseudo-Scr elevation appears to be a class effect of CDK4\/6i, with similar rates of Scr elevation observed across the three agents currently FDA approved.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241305417","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T03:38:49Z","timestamp":1733715529000},"page":"641-647","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of cyclin-dependent kinase 4\/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer"],"prefix":"10.1177","volume":"32","author":[{"given":"Emily","family":"Ly","sequence":"first","affiliation":[{"name":"University of Chicago Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick M","family":"Howard","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olwen","family":"Hahn","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F","family":"Fleming","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"University of Chicago Comprehensive Cancer Center, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Patel","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Thimothy","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0858-862X","authenticated-orcid":false,"given":"Heng","family":"Yang","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.9909"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30292-4"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_3_2_10_2","first-page":"1","article-title":"MONARCH 3 Final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston S","unstructured":"Johnston S, Martin M, Di Leo A, et al. MONARCH 3 Final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Cancer 2019 Jan 17; 5: 1\u20138.","journal-title":"Npj Breast Cancer"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_3_2_12_2","first-page":"1080","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Dennis S","unstructured":"Dennis S, Oleg L, Zbigniew N, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med 2024 Mar 20; 390: 1080\u20131091.","journal-title":"N Engl J Med"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1296"},{"key":"e_1_3_2_14_2","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo HS","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist 2021 Jan 1; 26: e53\u2013e65.","journal-title":"Oncologist"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/23993693211021420"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211007202"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/23993693221085285"},{"key":"e_1_3_2_18_2","first-page":"205435812211062","article-title":"Targeted cancer therapies causing elevations in Serum creatinine through tubular secretion inhibition: a case report and review of the literature","volume":"9","author":"Mach T","unstructured":"Mach T, Qi A, Bouganim N, et al. Targeted cancer therapies causing elevations in Serum creatinine through tubular secretion inhibition: a case report and review of the literature. Can J Kidney Health Dis 2022 Jun 21; 9: 20543581221106246.","journal-title":"Can J Kidney Health Dis"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14629"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad011"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1248"},{"key":"e_1_3_2_22_2","article-title":"Abstract P6-15-01: analysis of renal function in MONARCH 1: a phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+\/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC)","volume":"77","author":"Tolaney S","unstructured":"Tolaney S, Lam A, Mukundan S, et al. Abstract P6-15-01: analysis of renal function in MONARCH 1: a phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+\/HER2- breast cancer, after chemotherapy for metastatic breast cancer (MBC). Cancer Res 2017 Feb 15; 77: P6-15\u201301.","journal-title":"Cancer Res"},{"key":"e_1_3_2_23_2","article-title":"194P Increased blood creatinine level due to CDK4\/6 inhibitor treatments: single center experience","volume":"33","author":"Keskink\u0131l\u0131\u00e7 M","unstructured":"Keskink\u0131l\u0131\u00e7 M, Semiz HS, Yavuzsen T, et al. 194P Increased blood creatinine level due to CDK4\/6 inhibitor treatments: single center experience. Ann Oncol 2022 May 1; 33: S216.","journal-title":"Ann Oncol"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.11.033"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241305417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241305417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241305417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:55:14Z","timestamp":1779274514000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241305417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/10781552241305417"],"URL":"https:\/\/doi.org\/10.1177\/10781552241305417","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]}}}